在一項(xiàng)涉及了50000例患者的新藥臨床試驗(yàn)中，發(fā)現(xiàn)價格便宜的抗血小板藥物將clopidogrel添加到標(biāo)準(zhǔn)治療之中，能夠?qū)⑿呐K病發(fā)作患者入院治療1周后發(fā)生其它動脈阻塞或者心臟病二次發(fā)作的幾率降低了36％，

在該項(xiàng)臨床試驗(yàn)中患者有急性ST段升高的心肌缺血性梗死（STEMI）。在30天之后clopidogrel把心血管源性死亡、心肌梗死再發(fā)以及導(dǎo)致緊急血管再造的再發(fā)性缺血減少了20％。這項(xiàng)試驗(yàn)發(fā)現(xiàn)無論患者性別、接受的標(biāo)準(zhǔn)治療方案（纖維蛋白溶解類型或者肝素類型）或者心臟病發(fā)作的部位有何不同，結(jié)果都保持一致。

另外一項(xiàng)相同的臨床試驗(yàn)發(fā)現(xiàn)：除了標(biāo)準(zhǔn)治療方案之外，使用clopidogrel治療心臟病發(fā)作患者，把死亡的相對危險(xiǎn)降低了7％，心臟病復(fù)發(fā)的危險(xiǎn)降低了9％。英國牛津大學(xué)Zheng Ming Chen醫(yī)生說：“這項(xiàng)臨床試驗(yàn)還顯示：治療并不會顯著增加胎兒的風(fēng)險(xiǎn)或者與clopiogrel治療相關(guān)的輸血出血風(fēng)險(xiǎn)。”Zheng Ming Chen醫(yī)生在2005年3月美國奧蘭多(FL, USA)舉行的美國心臟病學(xué)院年會上報(bào)道了這些試驗(yàn)結(jié)果。

其它參與該項(xiàng)臨床試驗(yàn)的研究人員分別來自哈佛醫(yī)學(xué)院(Boston, MA, USA)、Brigham與婦女醫(yī)院(Boston, MA, USA)、中國北京阜外醫(yī)院以及中國醫(yī)學(xué)科學(xué)院。重大出血與顱內(nèi)出血發(fā)生率在兩個治療組中類似。Clopidogrel(clopidogrel bisulfate)在全球范圍內(nèi)是由Sanofi-Aventis公司 (Paris, France)和Bristol-Myers Squibb 公司 (Princeton, NJ, USA)推向市場的，名稱分別是Plavix與Iscover。
 
Drug Improves Heart-Attack Survival
 
One trial in a new study involving nearly 50,000 patients has shown that the inexpensive anti-platelet agent clopidogrel added to standard therapy reduced the odds of heart attack patients having another occluded artery or a second heart attack by 36% after one week of hospitalization.

Patients in the study had acute ST-segment elevation myocardial infarction (STEMI). After 30 days, clopidogrel reduced the odds of cardiovascular death, recurrent infarction, and recurrent ischemia leading to urgent revascularization by 20%. The results were consistent regardless of gender, the standard therapy received (type of fibrinolytic or type of heparin), or the location of the heart attack.

Another trial in the same study found that treating heart attack patients with clopidogrel in addition to standard therapy reduced the relative risk of death by 7% and the risk of a recurrent heart attack by 9%. “The study also showed that there was no significant increase in the risk of fetal or transfused bleeding associated with clopidogrel therapy,” said Zheng Ming Chen, M.D., University of Oxford (UK), who presented the findings at the annual meeting of the American College of Cardiology in Orlando (FL, USA) in March 2005.

Other researchers who took part in the study were from Harvard Medical School (Boston, MA, USA), Brigham and Women’s Hospital (also in Boston), and Fuwai Hospital and the Chinese Academy of Medical Sciences (both in Beijing, China). The rates of major bleeding and intracranial hemorrhage were similar in both treatment groups. Clopidogrel (clopidogrel bisulfate) is marketed worldwide by Sanofi-Aventis (Paris, France) and Bristol-Myers Squibb Company (Princeton, NJ, USA) as Plavix and Iscover.